Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II
Hawtin, Rachael E, Stockett, David E, Byl, Jo Ann W, McDowell, Robert S, Nguyen, Tan, Arkin, Michelle R, Conroy, Andrew, Yang, Wenjin, Osheroff, Neil, Fox, Judith A
Published in PloS one (15.04.2010)
Published in PloS one (15.04.2010)
Get full text
Journal Article
SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples
Conroy, Andrew, Stockett, David E, Walker, Duncan, Arkin, Michelle R, Hoch, Ute, Fox, Judith A, Hawtin, Rachael Elizabeth
Published in Cancer chemotherapy and pharmacology (01.09.2009)
Published in Cancer chemotherapy and pharmacology (01.09.2009)
Get full text
Journal Article
SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo
Arbitrario, Jennifer P, Belmont, Brian J, Evanchik, Marc J, Flanagan, W. Michael, Fucini, Raymond V, Hansen, Stig K, Harris, Shannon O, Hashash, Ahmad, Hoch, Ute, Hogan, Jennifer N, Howlett, Anthony R, Jacobs, Jeffrey W, Lam, Joni W, Ritchie, Sean C, Romanowski, Michael J, Silverman, Jeffrey A, Stockett, David E, Teague, Juli N, Zimmerman, Kristin M, Taverna, Pietro
Published in Cancer chemotherapy and pharmacology (01.03.2010)
Published in Cancer chemotherapy and pharmacology (01.03.2010)
Get full text
Journal Article
Abstract C222: Voreloxin is synergistic in in vitro combination with cytarabine and additive in combination with azacitidine, decitabine, and clofarabine
Stockett, David E., Kumer, Jeffrey L., Scatena, Carrie D., Silverman, Jeffrey A., Hawtin, Rachael E., Fox, Judith A.
Published in Molecular cancer therapeutics (10.12.2009)
Published in Molecular cancer therapeutics (10.12.2009)
Get full text
Journal Article